Kalos Management, Inc. Paratek Pharmaceuticals, Inc. Transaction History

Kalos Management, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.73 - $3.09 $865 - $1,545	-500 Reduced 3.44%	14,050 $27,000
Q1 2022 Jun 21, 2022	BUY	$2.94 - $4.77 $42,777 - $69,403	14,550 New	14,550 $43,000
Q4 2021 Feb 03, 2022	SELL	$4.07 - $5.3 $63,288 - $82,415	-15,550 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$4.7 - $7.24 $18,800 - $28,960	-4,000 Reduced 20.46%	15,550 $77,000
Q1 2021 May 13, 2021	SELL	$6.14 - $8.31 $15,350 - $20,775	-2,500 Reduced 11.34%	19,550 $138,000
Q4 2020 Feb 11, 2021	SELL	$4.58 - $7.14 $11,450 - $17,850	-2,500 Reduced 10.18%	22,050 $138,000
Q3 2020 Nov 12, 2020	SELL	$4.19 - $6.69 $2,095 - $3,345	-500 Reduced 2.0%	24,550 $136,000
Q3 2019 Nov 14, 2019	SELL	$3.08 - $5.76 $15,400 - $28,800	-5,000 Reduced 16.64%	25,050 $107,000
Q2 2019 Aug 14, 2019	BUY	$3.47 - $6.32 $12,086 - $22,012	3,483 Added 13.11%	30,050 $119,000
Q1 2019 May 15, 2019	BUY	$5.36 - $7.24 $11,347 - $15,327	2,117 Added 8.66%	26,567 $142,000
Q4 2018 Feb 13, 2019	BUY	$4.8 - $11.6 $52,800 - $127,600	11,000 Added 81.78%	24,450 $160,000
Q3 2018 Nov 14, 2018	BUY	$9.05 - $10.95 $121,722 - $147,277	13,450 New	13,450 $115,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Kalos Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kalos Management, Inc. with notifications on news.